Education
About Us
Working with TipRanks
Follow Us
PFIZER LIMITED (IN:PFIZER)
:PFIZER
Top Page
PFIZER LIMITED
(PFIZER)
Rating:63Neutral
Price Target:
₹5,452.00
▲(6.50% Upside)
PFIZER LIMITED (PFIZER) vs. iShares MSCI India ETF (INDA)
Market Cap
₹234.20B
Dividend Yield0.68%
Average Volume (3M)2.66K
Price to Earnings (P/E)29.0
Beta (1Y)0.65
Revenue Growth4.35%
EPS Growth32.89%
CountryIN
Employees1,721
SectorHealthcare
Sector Strength52
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)41.90
Shares Outstanding45,747,730
10 Day Avg. Volume1,519
30 Day Avg. Volume2,664
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹5,452.00Price Target Upside6.50% Upside
Rating ConsensusHold
Number of Analyst Covering1
PFIZER LIMITED Business Overview & Revenue Model
Company DescriptionPfizer Limited (PFIZER) is a leading global pharmaceutical corporation engaged in the discovery, development, manufacture, and marketing of healthcare products. The company operates in various sectors, including the development of medicines and vaccines across a wide range of therapeutic areas such as oncology, cardiology, immunology, and infectious diseases. Pfizer is renowned for its innovation in biopharmaceuticals and its contribution to public health with a comprehensive portfolio of products that address some of the most challenging medical conditions.
How the Company Makes MoneyPfizer makes money primarily through the research, development, and sale of pharmaceutical products. The company's revenue streams are driven by its diverse portfolio of patented medications, vaccines, and consumer healthcare products. Key revenue generators include blockbuster drugs, which are high-revenue-generating medications, and vaccines like the COVID-19 vaccine developed in partnership with BioNTech. Pfizer's business model includes collaborating with research institutions, biotechnology firms, and governments to enhance its product offerings. Additionally, the company's extensive global distribution network and strategic partnerships with healthcare providers and pharmacies play a significant role in its revenue generation by ensuring wide accessibility and availability of its products.
PFIZER LIMITED Earnings Call Summary
Earnings Call Date:Aug 13, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 27, 2025
Earnings Call Sentiment Positive
Pfizer's earnings call reflected a strong financial performance with solid revenue and EPS growth, driven by effective cost management and advancements in the R&D pipeline. However, challenges such as impacts from the IRA Medicare Part D redesign and ongoing geopolitical uncertainties pose potential risks.Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Pfizer recorded revenues of $14.7 billion for the second quarter, representing a 10% operational increase year-over-year.
Increased Earnings Guidance
Pfizer raised its adjusted diluted EPS guidance for the full year 2025 by $0.10, indicating strong performance and confidence in future results.
R&D Pipeline Advancements
Significant progress in the R&D pipeline with promising data for Elrexfio, SV, and Hympavzi, as well as the development of a C. diff vaccine.
Cost Management Success
Total adjusted operating expenses decreased by 8% operationally, demonstrating effective cost management strategies.
Strong Performance of Key Products
Products like Vyndaqel, Eliquis, and Padcev showed significant growth, with Vyndaqel growing 21% year-over-year operationally.
Negative Updates
Impact of IRA Medicare Part D Redesign
An $825 million year-over-year unfavorable impact due to higher manufacturer discounts resulting from the IRA Medicare Part D redesign.
Challenges with MFN and Tariffs
Ongoing discussions with the U.S. government regarding MFN and tariffs, creating uncertainty and potential future financial impacts.
Competitive Pressures in Oncology
Increased competition impacting the performance of ADCETRIS and TUKYSA, with pressure on growth despite strategic efforts.
Company Guidance
During Pfizer's Second Quarter 2025 Earnings Conference Call, the company provided updated guidance reflecting strong year-to-date performance. Specifically, Pfizer raised its adjusted diluted EPS guidance for the full year 2025, driven by productivity gains and strategic initiatives to expand margins. The company reported second-quarter revenues of $14.7 billion, a 10% operational increase, and adjusted diluted EPS of $0.78, surpassing expectations. Pfizer's robust operating margins were achieved amidst challenges such as an $825 million unfavorable impact from higher manufacturer discounts due to the IRA Medicare Part D redesign. Pfizer's non-COVID portfolio, including strong performers like the Vyndaqel family and Eliquis, contributed significantly to its solid financial outlook. The company maintained its full-year 2025 revenue guidance of $61 billion to $64 billion and adjusted its SI&A and R&D expense forecasts while expecting an adjusted effective tax rate of approximately 13%. Pfizer's strategic focus remains on enhancing R&D productivity, leveraging AI and digital capabilities, and optimizing capital allocation to create long-term shareholder value.PFIZER LIMITED Financial Statement Overview
Summary
PFIZER LIMITED displays strong financial performance with robust profitability, a solid balance sheet, and excellent cash flow management. The company maintains high margins, low leverage, and shows consistent improvement in key financial metrics, underscoring its competitive standing.Income Statement
PFIZER LIMITED has demonstrated strong profitability with a consistent gross profit margin above 60% and an increasing net profit margin, reaching 33.6% in the latest period. The company has shown a healthy EBIT margin of 48.2% and an EBITDA margin of 32.4% for the most recent year. Revenue growth has been somewhat volatile, but there is a positive growth trajectory from the previous year, indicating resilience in the market.85
Very Positive
Balance Sheet
The company's balance sheet is robust, with a low debt-to-equity ratio of 0.03, suggesting limited leverage and a strong equity cushion. The return on equity is impressive at 18.2%, indicating efficient use of equity. Additionally, the equity ratio stands at 85.9%, showing a strong capital structure with high asset backing.90
Very Positive
Cash Flow
PFIZER LIMITED exhibits a strong cash flow position. With a significant increase in free cash flow, the free cash flow growth rate is 165.5%. The operating cash flow to net income ratio is favorable at 0.86, and the free cash flow to net income ratio is 0.82, suggesting that the company efficiently converts profits into cash.92
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.81B | 22.81B | 24.25B | 21.93B | 26.11B | 22.38B |
| Gross Profit | 12.49B | 14.71B | 15.51B | 13.97B | 16.63B | 14.41B |
| EBITDA | 8.25B | 7.40B | 9.42B | 8.24B | 8.97B | 7.92B |
| Net Income | 7.68B | 7.68B | 6.24B | 5.51B | 6.13B | 4.98B |
Balance Sheet | ||||||
| Total Assets | 49.11B | 49.11B | 40.01B | 42.29B | 39.01B | 32.66B |
| Cash, Cash Equivalents and Short-Term Investments | 28.01B | 28.01B | 18.82B | 20.27B | 16.10B | 10.98B |
| Total Debt | 1.08B | 1.08B | 1.34B | 945.40M | 1.67B | 1.06B |
| Total Liabilities | 6.94B | 6.94B | 7.93B | 6.33B | 10.36B | 8.73B |
| Stockholders Equity | 42.17B | 42.17B | 32.07B | 35.96B | 28.64B | 23.93B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 6.32B | 2.91B | 2.38B | 6.52B | 4.10B |
| Operating Cash Flow | 0.00 | 6.60B | 3.56B | 2.57B | 6.67B | 4.27B |
| Investing Cash Flow | 0.00 | -713.40M | -360.50M | -751.30M | -5.75B | -4.69B |
| Financing Cash Flow | 0.00 | -2.05B | -3.46B | -2.35B | -1.81B | -15.71B |
PFIZER LIMITED Technical Analysis
Positive
5119.45
Price Trends
5353.46
Negative
5082.16
Positive
4794.09
Positive
Market Momentum
-36.88
Positive
42.63
Neutral
9.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PFIZER, the sentiment is Positive. The current price of 5119.45 is below the 20-day moving average (MA) of 5286.16, below the 50-day MA of 5353.46, and above the 200-day MA of 4794.09, indicating a neutral trend. The MACD of -36.88 indicates Positive momentum. The RSI at 42.63 is Neutral, neither overbought nor oversold. The STOCH value of 9.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PFIZER.
PFIZER LIMITED Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹638.05B | 27.93 | 0.84% | 4.49% | 11.22% | ||
67 Neutral | ₹227.20B | 123.91 | 0.35% | 33.69% | 91.28% | ||
63 Neutral | ₹234.20B | 28.96 | 0.68% | 4.35% | 32.89% | ||
60 Neutral | ₹338.70B | 43.51 | 0.30% | 11.49% | 35.00% | ||
54 Neutral | ₹579.50B | 76.88 | 0.12% | 10.99% | ― | ||
51 Neutral | $7.95B | -0.40 | -41.62% | 2.21% | 22.29% | -1.85% | |
| ― | ₹113.09B | 22.79 | 3.96% | ― | ― |
* Healthcare Sector Average
Performance Comparison
IN:PFIZER
PFIZER LIMITED
5,119.45
-859.70
-14.38%
IN:ALKEM
Alkem Laboratories Ltd.
5,336.45
-868.08
-13.99%
IN:ASTRAZEN
AstraZeneca Pharma India Limited
9,088.15
2,342.68
34.73%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,053.50
347.00
20.33%
IN:GLS
Glenmark Life Sciences Limited
921.85
-279.85
-23.29%
IN:IPCALAB
IPCA Laboratories Limited
1,335.25
-63.96
-4.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.